REG-Bioventix Plc: Interim Dividend Confirmation

BioventixAnnouncement

29/03/2022 07:15

Bioventix plc

(“Bioventix” or the “Company”)

Interim dividend confirmation

Bioventix plc (BVXP) (“Bioventix” or “the Company”), a UK company
specialising in the development and commercial supply of high-affinity
monoclonal antibodies for applications in clinical diagnostics, announces that
the Board has confirmed a cash interim dividend of 52p per ordinary share,
which will be paid on 22 April 2022.

The dividend timetable dates are below:

 Ex-dividend date:  7 April 2022   
 Record date:       8 April 2022   
 Payment date:      22 April 2022  

For further information please contact:

Bioventix plc
Peter Harrison 
Chief Executive Officer  Tel: 01252 728 001

finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane         
Corporate Finance
ECM      Tel: 020 7220 0500

About Bioventix plc:

Bioventix (www.bioventix.com) specialises in the development and commercial
supply of high-affinity monoclonal antibodies with a primary focus on their
application in clinical diagnostics, such as in automated immunoassays used in
blood testing. The antibodies created at Bioventix are generated in sheep and
are of particular benefit where the target is present at low concentration and
where conventional monoclonal or polyclonal antibodies have failed to produce
a suitable reagent. Bioventix currently offers a portfolio of antibodies to
customers for both commercial use and R&D purposes, for the diagnosis or
monitoring of a broad range of conditions, including heart disease, cancer,
fertility, thyroid function and drug abuse. Bioventix currently supplies
antibody products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its shares are
traded on AIM under the symbol BVXP.



Copyright (c) 2022 PR Newswire Association,LLC. All Rights Reserved